1. Home
  2. ICD-10 PCS Codes
  3. X
  4. W
  5. 0
  6. 3 - Peripheral Vein

Peripheral Vein

  • XW033 - Percutaneous
    • XW0330
      • XW03306 - Introduction Peripheral Vein to New Technology Group 6 with Brexanolone, Percutaneous Approach
      • XW03308 - Introduction Peripheral Vein to New Technology Group 8 with Spesolimab Monoclonal Antibody, Percutaneous Approach
    • XW0332
      • XW03326 - Introduction Peripheral Vein to New Technology Group 6 with Nerinitide, Percutaneous Approach
    • XW0333
      • XW03336 - Introduction Peripheral Vein to New Technology Group 6 with Durvalumab Antineoplastic, Percutaneous Approach
      • XW0333A - Introduction Peripheral Vein to New Technology Group 10 with Bentracimab, Ticagrelor Reversal Agent, Percutaneous Approach
    • XW0334
      • XW0334A - Introduction Peripheral Vein to New Technology Group 10 with Cefepime-taniborbactam Anti-infective, Percutaneous Approach
    • XW0335
      • XW03357 - Introduction Peripheral Vein to New Technology Group 7 with Narsoplimab Monoclonal Antibody, Percutaneous Approach
      • XW03358 - Introduction Peripheral Vein to New Technology Group 8 with Mosunetuzumab Antineoplastic, Percutaneous Approach
      • XW0335A - Introduction Peripheral Vein to New Technology Group 10 with Ceftobiprole Medocaril Anti-infective, Percutaneous Approach
    • XW0336
      • XW03366 - Introduction Peripheral Vein to New Technology Group 6 with Lefamulin Anti-infective, Percutaneous Approach
      • XW03367 - Introduction Peripheral Vein to New Technology Group 7 with Terlipressin, Percutaneous Approach
      • XW03368 - Introduction Peripheral Vein to New Technology Group 8 with Afamitresgene Autoleucel Immunotherapy, Percutaneous Approach
    • XW0337
      • XW03372 - Introduction Peripheral Vein to New Technology Group 2 with Coagulation Factor Xa, Inactivated, Percutaneous Approach
      • XW03377 - Introduction Peripheral Vein to New Technology Group 7 with Trilaciclib, Percutaneous Approach
      • XW03378 - Introduction Peripheral Vein to New Technology Group 8 with Tabelecleucel Immunotherapy, Percutaneous Approach
    • XW0338
      • XW03387 - Introduction Peripheral Vein to New Technology Group 7 with Lurbinectedin, Percutaneous Approach
      • XW03388 - Introduction Peripheral Vein to New Technology Group 8 with Treosulfan, Percutaneous Approach
      • XW0338A - Introduction Peripheral Vein to New Technology Group 10 with Obecabtagene Autoleucel, Percutaneous Approach
    • XW0339
      • XW03396 - Introduction Peripheral Vein to New Technology Group 6 with Ceftolozane/Tazobactam Anti-infective, Percutaneous Approach
      • XW03398 - Introduction Peripheral Vein to New Technology Group 8 with Inebilizumab-cdon, Percutaneous Approach
      • XW0339A - Introduction Peripheral Vein to New Technology Group 10 with Odronextamab Antineoplastic, Percutaneous Approach
    • XW033A
      • XW033A6 - Introduction Peripheral Vein to New Technology Group 6 with Cefiderocol Anti-infective, Percutaneous Approach
      • XW033A7 - Introduction Peripheral Vein to New Technology Group 7 with Ciltacabtagene Autoleucel, Percutaneous Approach
    • XW033B
      • XW033B3 - Introduction Peripheral Vein to New Technology Group 3 with Cytarabine and Daunorubicin Liposome Antineoplastic, Percutaneous Approach
      • XW033B6 - Introduction Peripheral Vein to New Technology Group 6 with Omadacycline Anti-infective, Percutaneous Approach
      • XW033B7 - Introduction Peripheral Vein to New Technology Group 7 with Amivantamab Monoclonal Antibody, Percutaneous Approach
      • XW033BA - Introduction Peripheral Vein to New Technology Group 10 with Orca-T Allogeneic T-cell Immunotherapy, Percutaneous Approach
    • XW033C
      • XW033C6 - Introduction Peripheral Vein to New Technology Group 6 with Eculizumab, Percutaneous Approach
      • XW033C7 - Introduction Peripheral Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous, Percutaneous Approach
      • XW033CA - Introduction Peripheral Vein to New Technology Group 10 with Zanidatamab Antineoplastic, Percutaneous Approach
    • XW033D
      • XW033D6 - Introduction Peripheral Vein to New Technology Group 6 with Atezolizumab Antineoplastic, Percutaneous Approach
      • XW033DA - Introduction Peripheral Vein to New Technology Group 10 with Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension, Percutaneous Approach
    • XW033E
      • XW033E5 - Introduction Peripheral Vein to New Technology Group 5 with Remdesivir Anti-infective, Percutaneous Approach
      • XW033E6 - Introduction Peripheral Vein to New Technology Group 6 with Etesevimab Monoclonal Antibody, Percutaneous Approach
    • XW033F
      • XW033F3 - Introduction Peripheral Vein to New Technology Group 3 with Other New Technology Therapeutic Substance, Percutaneous Approach
      • XW033F5 - Introduction Peripheral Vein to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach
      • XW033F6 - Introduction Peripheral Vein to New Technology Group 6 with Bamlanivimab Monoclonal Antibody, Percutaneous Approach
      • XW033FA - Introduction Peripheral Vein to New Technology Group 10 with Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy, Percutaneous Approach
    • XW033G
      • XW033G5 - Introduction Peripheral Vein to New Technology Group 5 with Sarilumab, Percutaneous Approach
      • XW033G6 - Introduction Peripheral Vein to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach
      • XW033G7 - Introduction Peripheral Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic, Percutaneous Approach
    • XW033H
      • XW033H5 - Introduction Peripheral Vein to New Technology Group 5 with Tocilizumab, Percutaneous Approach
      • XW033H6 - Introduction Peripheral Vein to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach
      • XW033H7 - Introduction Peripheral Vein to New Technology Group 7 with Axicabtagene Ciloleucel Immunotherapy, Percutaneous Approach
    • XW033J
      • XW033J7 - Introduction Peripheral Vein to New Technology Group 7 with Tisagenlecleucel Immunotherapy, Percutaneous Approach
    • XW033K
      • XW033K7 - Introduction Peripheral Vein to New Technology Group 7 with Idecabtagene Vicleucel Immunotherapy, Percutaneous Approach
      • XW033K9 - Introduction Peripheral Vein to New Technology Group 9 with Sulbactam-Durlobactam, Percutaneous Approach
    • XW033L
      • XW033L6 - Introduction Peripheral Vein to New Technology Group 6 with CD24Fc Immunomodulator, Percutaneous Approach
      • XW033L7 - Introduction Peripheral Vein to New Technology Group 7 with Lifileucel Immunotherapy, Percutaneous Approach
    • XW033M
      • XW033M7 - Introduction Peripheral Vein to New Technology Group 7 with Brexucabtagene Autoleucel Immunotherapy, Percutaneous Approach
    • XW033N
      • XW033N7 - Introduction Peripheral Vein to New Technology Group 7 with Lisocabtagene Maraleucel Immunotherapy, Percutaneous Approach
    • XW033P
      • XW033P9 - Introduction Peripheral Vein to New Technology Group 9 with Glofitamab Antineoplastic, Percutaneous Approach
    • XW033Q
      • XW033Q5 - Introduction Peripheral Vein to New Technology Group 5 with Tagraxofusp-erzs Antineoplastic, Percutaneous Approach
      • XW033Q9 - Introduction Peripheral Vein to New Technology Group 9 with Posoleucel, Percutaneous Approach
    • XW033R
      • XW033R9 - Introduction Peripheral Vein to New Technology Group 9 with Rezafungin, Percutaneous Approach
    • XW033S
      • XW033S5 - Introduction Peripheral Vein to New Technology Group 5 with Iobenguane I-131 Antineoplastic, Percutaneous Approach
    • XW033W
      • XW033W5 - Introduction Peripheral Vein to New Technology Group 5 with Caplacizumab, Percutaneous Approach